Compass Group PLC Sponsored ADR (CMPGY)
Compass Group Q2 Earnings Call Highlights
Compass Group LON: CPG raised its full-year profit outlook after reporting what management described as “another very strong half,” with operating profit up 12% and organic revenue growth a little above 7%.
Compass Minerals International Q2 Earnings Call Highlights
Compass Minerals International NYSE: CMP reported improved profitability in its fiscal second quarter despite lower revenue, as management pointed to stronger margins, progress in its Plant Nutrition business and a major debt reduction milestone.
Compass Diversified Q1 Earnings Call Highlights
Compass Diversified NYSE: CODI reported first-quarter 2026 results that management characterized as a period of execution, highlighted by a divestiture, debt reduction and growth in subsidiary adjusted EBITDA despite macroeconomic uncertainty.
Compass, Inc. (COMP) Q1 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q1 2026 Earnings Call Transcript
Compass, Inc. (COMP) Q1 Earnings and Revenues Top Estimates
Compass, Inc. (COMP) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.05 per share a year ago.
Compass, Inc. (COMP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Compass (COMP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compass Minerals: Pittsburgh's Ice Reveals The Value Chain
Compass Minerals holds structural advantages in salt production, with irreplaceable assets and geographic reach supporting a premium market position. Loss of the SHACOG contract impacts only about 1% of CMP's total volumes, with the company prioritizing value over volume in its strategic outlook. Industry dynamics have shifted favorably for CMP after Cargill's exit, depleted inventories, and early bid season price increases, supporting higher EBITDA potential.
Compass Pathways: Red Hot Psychedelic Market For Pioneer With Near Term Psychedelic Filing In TRD
Compass Pathways plc (CMPS) has faced significant risks since my last 'Buy' rating in January 2026. CMPS shares had declined approximately 10% over the intervening months, but then registered huge gains in three market days after White House announcement. The investment thesis previously emphasized exciting prospects, but risk factors had dominated recent performance prior to White House action.
Compass Pathways: The Bull Case Is Early, Not Wrong
COMPASS Pathways plc is developing pharmaceutical-grade psilocybin treatments for severe mental health conditions, notably treatment-resistant depression. CMPS remains a pipeline-stage biotech with no current sales, as its lead product, COMP360, is still in clinical trials. A recent executive order aims to accelerate access to psychedelic drug research and treatments, potentially benefiting CMPS's regulatory pathway.
Compass: Clarity Is Lacking, But I'm Bullish Anyway
Compass, Inc. remains a Buy following its transformative merger with Anywhere Real Estate, despite recent underperformance versus the S&P 500. COMP's pro forma EBITDA could reach $643.4M, or up to $868.4M with full $225M in expected cost synergies, making valuation compelling. Net debt has risen to $2.25B post-merger, but improved cash flow and scale from new brands and services support the investment thesis.
Rocket's AI Push and Compass Deal Could Shift Mortgage Share
RKT bets on AI, servicing scale and a Compass deal to drive mortgage share gains, but execution risks and housing headwinds cloud timing.
Compass Diversified's $292M Sale Ignites Stock
Compass Diversified's recent divestiture provides the company with substantial capital to significantly reduce its debt and improve its overall financial flexibility.
